CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Analysis of Bioanalytical Services Market

Analysis of Bioanalytical Services...

Trudiagnostic Unveils Truage PACE For Tracking Biological Aging Rate

Trudiagnostic Unveils Truage PACE For...

Know More About the Comprehensive Bioanalytical Testing Services

Know More About the Comprehensive...

Ways Bioanalytical Laboratory Automation Boosts Efficiency and Accuracy

Ways Bioanalytical Laboratory...

Analytics' Role in Pharmaceutical Success

Analytics' Role in Pharmaceutical...

Discovering and developing drugs using bioanalysis

Discovering and developing drugs...

Developing Next-Generation Technologies for a Better Tomorrow

Developing Next-Generation...

Why Outsource Bioanalysis Work?

Why Outsource Bioanalysis Work?

Analysis of Bioanalytical Services Market

Analysis of Bioanalytical Services...

Trudiagnostic Unveils Truage PACE For Tracking Biological Aging Rate

Trudiagnostic Unveils Truage PACE For...

Know More About the Comprehensive Bioanalytical Testing Services

Know More About the Comprehensive...

Ways Bioanalytical Laboratory Automation Boosts Efficiency and Accuracy

Ways Bioanalytical Laboratory...

Analytics' Role in Pharmaceutical Success

Analytics' Role in Pharmaceutical...

Discovering and developing drugs using bioanalysis

Discovering and developing drugs...

Developing Next-Generation Technologies for a Better Tomorrow

Developing Next-Generation...

Why Outsource Bioanalysis Work?

Why Outsource Bioanalysis Work?

Biosplice Therapeutics Raises $ 120 M in Equity Funding

Life Sciences Review Life Sciences Review | Wednesday, April 28, 2021
Tweet

Eventide Asset Management, aMoon, SymBiosis II, Sands Capital, Verition Fund Management, and others are among the investors in this latest round, which also includes established investor support.


FREMONT, CA: Biosplice Therapeutics (Biosplice), a clinical-stage biotechnology company that is developing therapeutics for major diseases based on alternative pre-mRNA splicing, announced that it has raised 120 million dollars in equity funding from a new biotechnology investment syndicate. Eventide Asset Management, aMoon, SymBiosis II, Sands Capital, Verition Fund Management, and others are among the investors in this latest round, which also includes established investor support. Joy Ghosh, Ph.D., of Eventide Asset Management, and Gur Roshwalb, MD, of aMoon will join the company’s Board of Directors as part of the financing.


“We are delighted to align with our new investors and board behind the immense therapeutic potential of Biosplice,” said CevdetSamikoglu, Chief Executive Officer of Biosplice. “This investment round positions us to accelerate the development and launch of lorecivivint, our groundbreaking Phase 3 program in osteoarthritis. In addition, we expect to realize the tremendous potential of our oncology program, as well as neurology and other areas of significant unmet need.”


Biosplice is designing small-molecule therapeutics that are first-in-class, based on the cutting-edge technology of alternative pre-mRNA splicing. Biosplice has elucidated novel biology connecting CLK/DYRK kinases to the therapeutic control of alternative splicing, based on foundational discoveries in Wnt pathway modulation. Alternative splicing is a crucial biological process that controls the diversity of proteins in a cell, which determines the cell’s form and function. Within the cellular command and control center, the Biosplices target class controls the selection of tissue-specific mRNA splice sites, rendering them attractive, druggable targets.


Joy Ghosh, Ph.D., of Eventide Asset Management, added, “Biosplices alternative splicing platform has enormous potential to address critical needs in osteoarthritis, oncology and neurology, among others. We are particularly excited by lorecivivint, which has the potential to be a first-in-class medicine that could confer both symptomatic and disease-modifying benefits to hundreds of millions of osteoarthritis sufferers worldwide.”


Weekly Brief

loading
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/biosplice-therapeutics-raises-120-m-in-equity-funding-nwid-342.html